Opinion

Video

Biologic Therapies for Hidradenitis Suppurativa

Author(s):

Vivian Shi, MD, FAAD

A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.

Video content above is prompted by the following questions:

  • What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
  • Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?
Related Videos
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
Related Content
Book titled hidradenitis suppurativa | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
September 25th 2024

Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients

Brooke McCormick
A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.
Semaglutide | Image Credit: Corona Borealis - stock.adobe.com
September 24th 2024

Semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity

Cameron Santoro
Semaglutide treatment significantly improved quality of life and reduced flare-ups in patients with obesity and hidradenitis suppurativa.
Diversity animation | Image Credit: annaspoka - stock.adobe.com
September 17th 2024

Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color

Brooke McCormick
Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.
Silhouettes of different skin colors | Image Credit: freshidea - stock.adobe.com
September 17th 2024

Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials

Brooke McCormick
Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.
FDA approved stamp | Image Credit: Olivier Le Moal - stock.adobe.com
September 16th 2024

FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis

Brooke McCormick
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Image Credit: Andrew Popov - stock.adobe.com
September 13th 2024

Experts Highlight New Dermatological Treatments, Importance of Clinical Trial Diversity

Brooke McCormick
Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and emphasized the importance of clinical trial diversity.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo